Savara (NASDAQ:SVRA) Stock Price Down 8.5% – Time to Sell?

Savara Inc (NASDAQ:SVRA)’s stock price traded down 8.5% on Friday . The stock traded as low as $2.83 and last traded at $2.92. 559,788 shares were traded during trading, a decline of 54% from the average session volume of 1,209,018 shares. The stock had previously closed at $3.19.

Analyst Ratings Changes

SVRA has been the subject of a number of analyst reports. Evercore ISI restated an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research report on Wednesday. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Tuesday, October 1st. Finally, HC Wainwright cut their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Stock Performance

The firm has a market cap of $511.43 million, a PE ratio of -6.93 and a beta of 1.02. The business has a 50 day simple moving average of $3.88 and a two-hundred day simple moving average of $4.19. The company has a quick ratio of 11.31, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). As a group, equities research analysts forecast that Savara Inc will post -0.44 earnings per share for the current fiscal year.

Institutional Trading of Savara

Institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC increased its holdings in Savara by 41.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after purchasing an additional 746,407 shares during the period. Vanguard Group Inc. increased its stake in shares of Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares during the period. Swiss National Bank bought a new stake in shares of Savara in the first quarter valued at about $732,000. Frazier Life Sciences Management L.P. raised its holdings in shares of Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after acquiring an additional 4,157,385 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the period. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.